Bone donsitometry. Disorders of other endocrine glands in diseases classified elsewhere
Conditions
Interventions
Intervention 1: Intervention group: 2000 IU of vitamin D3 from 26-28
weeks gestation daily until delivery. Intervention 2: control group: placebo from 26-28 weeks gestation daily
until delivery or rou
Prevention
Intervention group: 2000 IU of vitamin D3 from 26-28
weeks gestation daily until delivery
control group: placebo from 26-28 weeks gestation daily
until delivery or routine care
Sponsors
Shiraz Univercity of Medical Sciences
Eligibility
Sex/Gender
All
Age
No minimum to 2 Months
Inclusion criteria
Inclusion criteria: Inclusion criteria: willingness to participate in the study; aged 18 years or older; at 26- 28 weeks gestation based on ultrasound; alive and singleton fetus; without a history of cesarean section; without a history of any disease; free of complication in present pregnancy; Exclusion criteria: cancellation of continuing the cooperation by the participants; taking vitamin D supplements less than 8 weeks ; nonhealthy newborn; newborn with any gross anomally
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood cord vit D concentration. Timepoint: After Delivery. Method of measurement: ELISA or another avialable method.;Bone densitometry. Timepoint: during first two months after birth. Method of measurement: Radiology and DXA method.;Antropometric measurments (height, weight and head circumference). Timepoint: At birth, at 4 and 8 weeks later. Method of measurement: Metric system. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarideh Vaziri
Shiraz University of Medical Sciences
Outcome results
None listed